Complaining about the valuation on Novo Nordisk (NVO) shares is a fruitless exercise. It's one of the strongest growth stories in healthcare, and so long as the company continues to execute, those premium multiples are likely to stay in place. I don't really embrace the "buy high, sell higher" philosophy, but it's difficult for me to ignore the growth and potential at this highly-focused biopharmaceutical company.
Continue reading here:
Novo Nordisk Still A Top-Notch Healthcare Growth Story